Black Diamond Therapeutics (NASDAQ:BDTX – Get Free Report) is expected to issue its quarterly earnings data before the market opens on Tuesday, March 11th. Analysts expect the company to announce earnings of ($0.31) per share for the quarter.
Black Diamond Therapeutics Price Performance
BDTX stock opened at $1.91 on Tuesday. The company has a 50 day moving average price of $2.27 and a 200 day moving average price of $3.29. Black Diamond Therapeutics has a fifty-two week low of $1.88 and a fifty-two week high of $7.66. The stock has a market capitalization of $108.08 million, a PE ratio of -1.44 and a beta of 2.51.
Analyst Upgrades and Downgrades
Separately, HC Wainwright restated a “buy” rating and issued a $11.00 price objective on shares of Black Diamond Therapeutics in a research report on Wednesday, November 6th.
About Black Diamond Therapeutics
Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.
Read More
- Five stocks we like better than Black Diamond Therapeutics
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- Bearish Investors Can Seek Refuge in Recession-Resistant ETFs
- Should You Invest in Penny Stocks?
- 3 Oversold Magnificent Seven Stocks at Key Levels: Buy Now?
- Consumer Staples Stocks, Explained
- 3M to Hit $175 by Mid-Year, and Higher Highs Are Likely
Receive News & Ratings for Black Diamond Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Black Diamond Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
